CAMBRIDGE, Mass., March 6, 2024 (Globe Newswire) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, is expanding its portfolio in areas of high unmet need, including rare diseases. We are focused on identifying and developing treatments for. The company announced today that it will hold a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report and provide an overview of its fourth quarter and full year financial results. . Latest information on business and pipeline.
To access the call, dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and reference conference ID 13744458 or click this link to request a call back please. Audio webcasts can be accessed from the Events & Presentations page under the Connect tab on the company's website at: www.sperotherapeutics.com. The archived webcast will also be available for viewing on Spero's website for 30 days after the call.
About Spero Therapeutics
Headquartered in Cambridge, Massachusetts, Spero Therapeutics is an asset-rich, clinical-stage company focused on identifying and developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections with high unmet need. A biopharmaceutical company.
-
Spero Therapeutics is developing SPR720 as a novel oral therapeutic candidate for the treatment of a rare orphan lung disease caused by non-tuberculous mycobacterial infections.
-
Tebipenem HBr is an investigational drug being developed in the United States for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria in adult patients with limited treatment options. . Tebipenem HBr is not approved by the U.S. Food and Drug Administration (FDA).
-
Spero Therapeutics also has SPR206, an IV-administered next-generation polymyxin product candidate developed from its potentiator platform in development to treat MDR Gram-negative infections in hospital settings.
For more information, please visit: https://sperotherapeutics.com.
Investor Information Contact:
Ted Jenkins
Vice President of Investor Relations and Strategic Finance
IR@sperotherapeutics.com
(617) 798-4039
Media inquiries:
Lora Grassilli, Health Media Relations
xeno group
lora.grassilli@zenogroup.com
646-932-3735
